Towa Pharmaceutical Co (6QC) Stock Price & Analysis

6QC Stock Chart & Stats

€19.50€0.20(1.04%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: EUR 19.50 - EUR 19.50
52-Week Range: EUR 15.20 - EUR 23.60
Previous Close: EUR 19.30
Volume: 0
Average Volume (3M): 0
Market Cap: EUR 981.17M
Enterprise Value: EUR 375.50B
Total Cash (Recent Filing): EUR 42.23B
Total Debt (Recent Filing): EUR 229.93B
Price to Earnings (P/E): 21.0
Beta: 0.43
Next Earnings: Nov 11, 2026 (Est.)
EPS Estimate: 0.57
Next Dividend Ex-Date: N/A
Dividend Yield: 1.99%

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Continued top-line expansion indicates that Towa is still increasing sales despite pressure on earnings. Sustained revenue growth supports portfolio scale, helps absorb fixed manufacturing costs, and provides a foundation for restoring profitability as operating execution improves.

Stable Gross Margin

A stable gross margin suggests that core pricing and production economics have remained resilient while revenue expanded. This provides an important base for future earnings recovery, because improved cost control or operating efficiency could flow through from a relatively consistent gross-profit structure.

Broad Generic Portfolio

A broad portfolio across multiple therapeutic areas gives Towa diversified product exposure within Japan's generic-drug market. The model combines development, manufacturing, and commercialization, supporting recurring prescription sales and reducing reliance on a single medicine or treatment category.

Bears Say

Profitability Compression

Sharp deterioration in net and EBIT margins means revenue growth is currently producing much less earnings than in prior periods. If this persists, weaker internal profit generation could constrain reinvestment, reduce returns on the business, and make recovery dependent on successful cost improvement.

Elevated Leverage

Higher debt relative to equity increases the financial burden at a time when profitability and ROE have weakened. This combination reduces balance-sheet flexibility, leaves less room to absorb operating setbacks, and may limit the company's ability to fund growth or return capital while earnings remain under pressure.

Weak Cash Conversion

Thin and volatile free cash flow indicates that accounting earnings are not consistently translating into surplus cash after investment needs. Weak conversion can restrict internally funded expansion, make cash returns less dependable, and increase the importance of disciplined spending and working-capital execution.

Towa Pharmaceutical Co News

Towa Pharmaceutical Delays Tanabe Pharma Factory Share Transfer to December

Towa Pharmaceutical Co ( ($JP:4553) ) has shared an update. Towa Pharmaceutical has announced a rescheduling of its planned acquisition of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation,

2d ago6QC TWAPF

Towa Pharmaceutical Clarifies Segment Structure in Q1 FY2027 Disclosure

Towa Pharmaceutical Co ( ($JP:4553) ) has shared an update. Towa Pharmaceutical has released supplementary materials for its first-quarter financial results for the fiscal year ending March 31, 2027, clarifying

2M ago6QC TWAPF

Towa Pharmaceutical Delivers Profit Surge and Keeps Robust Outlook

Towa Pharmaceutical Co ( ($JP:4553) ) just unveiled an announcement. Towa Pharmaceutical reported strong first-quarter results for the fiscal year ending March 31, 2027, with net sales rising 9.6% year

2M ago6QC TWAPF

Towa Pharmaceutical Completes ¥10 Billion Class A Preferred Share Issuance and Capital Restructuring

An update from Towa Pharmaceutical Co ( ($JP:4553) ) is now available. Towa Pharmaceutical Co., Ltd. has completed payment for the issuance of its 1st Series Class A preferred shares

3M ago6QC TWAPF

Towa Pharmaceutical Completes Restricted Stock Compensation Share Disposal

Towa Pharmaceutical Co ( ($JP:4553) ) has shared an announcement. Towa Pharmaceutical has completed the payment procedures for the disposal of 1,188 shares of its treasury stock under a restricted

3M ago6QC TWAPF

Towa Pharma to Acquire Tanabe Pharma Factory and Expand Off‑Patent Drug Portfolio

Towa Pharmaceutical Co ( ($JP:4553) ) just unveiled an update. Towa Pharmaceutical has agreed to acquire all shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation, turning it

4M ago6QC TWAPF

Towa Pharmaceutical Clarifies Relationship With Controlling Shareholder YOSHIDA JIMUSHO

An announcement from Towa Pharmaceutical Co ( ($JP:4553) ) is now available. Towa Pharmaceutical disclosed that YOSHIDA JIMUSHO, classified as another affiliated company, holds a total of 45.75% of its

4M ago6QC TWAPF

Towa Pharmaceutical Details Parent Firm Ownership and Governance Structure

Towa Pharmaceutical Co ( ($JP:4553) ) has provided an update. Towa Pharmaceutical disclosed the financial results and corporate profile of its parent company, YOSHIDA JIMUSHO, for the fiscal year ended

4M ago6QC TWAPF

Towa Pharmaceutical Grants Restricted Treasury Shares to Directors Under Long-Term Incentive Plan

The latest update is out from Towa Pharmaceutical Co ( ($JP:4553) ). Towa Pharmaceutical’s board has approved the disposal of 1,188 treasury shares as restricted stock, valued at about ¥4.56

4M ago6QC TWAPF

Towa Pharmaceutical Reshapes Board with New Strategy and Governance Appointments

The latest update is out from Towa Pharmaceutical Co ( ($JP:4553) ). Towa Pharmaceutical Co., Ltd. announced changes to its executive lineup following approvals at its Ordinary General Meeting of

4M ago6QC TWAPF

Towa Pharmaceutical upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Jaeheon Lee upgraded Towa Pharmaceutical (TWAPF) to Overweight from Equal Weight with a price target of 5,600 yen, up from 4,500 yen, citing clearer earnings growth potential

4M ago6QC TWAPF

6QC FAQ

What was Towa Pharmaceutical Co’s price range in the past 12 months?

Towa Pharmaceutical Co lowest stock price was €15.20 and its highest was €23.60 in the past 12 months.

What is Towa Pharmaceutical Co’s market cap?

Towa Pharmaceutical Co’s market cap is €981.17M.

When is Towa Pharmaceutical Co’s upcoming earnings report date?

Towa Pharmaceutical Co’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is in 9 days.

How were Towa Pharmaceutical Co’s earnings last quarter?

Towa Pharmaceutical Co released its earnings results on Aug 06, 2026. The company reported €0.636 earnings per share for the quarter.

Is Towa Pharmaceutical Co overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Towa Pharmaceutical Co pay dividends?

Towa Pharmaceutical Co does not currently pay dividends.

What is Towa Pharmaceutical Co’s EPS estimate?

Towa Pharmaceutical Co’s EPS estimate is 0.57.

How many shares outstanding does Towa Pharmaceutical Co have?

Towa Pharmaceutical Co has 51,516,000 shares outstanding.

What happened to Towa Pharmaceutical Co’s price movement after its last earnings report?

Towa Pharmaceutical Co reported an EPS of €0.636 in its last earnings report. Following the earnings report the stock price went up 1.925%.

Which hedge fund is a major shareholder of Towa Pharmaceutical Co?

Currently, no hedge funds are holding shares in DE:6QC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description